Helex Bio

Executive Summary

Helex Bio is an early-stage biotech company developing non-viral, kidney-targeted gene-editing therapies for chronic kidney diseases, with an initial focus on Autosomal Dominant Polycystic Kidney Disease (ADPKD). Founded in 2020 and based in Bengaluru, India, the company leverages a proprietary lipid nanoparticle (LNP) delivery platform and the Epic-Cure™ intelligent drug-design system to create safe, scalable, and affordable genomic medicines. By integrating epigenetic and 3D genome data, Helex aims to de-risk therapeutic design, potentially overcoming limitations of viral vectors and enabling precise editing of kidney cells. The company has raised $3.5 million and operates at a preclinical stage, positioning itself to address a significant unmet need in the global ADPKD market. The chronic kidney disease market, particularly ADPKD, represents a substantial opportunity due to limited treatment options and high patient burden. Helex’s kidney-targeted LNP approach offers potential advantages in safety, scalability, and cost compared to viral-based gene therapies. While still in preclinical development, the company’s AI-driven design and focus on de-risked targets could accelerate its path to the clinic. Key near-term milestones include completion of IND-enabling studies and securing additional funding to advance toward a first-in-human trial. If successful, Helex could become a leader in non-viral gene editing for renal diseases.

Upcoming Catalysts (preview)

• H2 2026Preclinical efficacy data in ADPKD animal models70% success
• Q1 2027Series A financing round60% success
• Q4 2026Completion of IND-enabling studies50% success